Review identifies factors leading to better outcome for some metastatic breast cancer patients

September 29, 1999

DURHAM, N.C.--Duke University Medical Center researchers have identified a subset of patients with advanced breast cancer who had greater success than other patients treated with experimental high-dose chemotherapy followed by bone marrow transplant.

In a retrospective review of a previous Duke study of 425 patients, now with an average of six years' follow-up, of the 299 patients who had high-dose chemotherapy with transplant, those patients who had previously received hormone therapy with the drug tamoxifen, but had not previously received chemotherapy and had no tumors beyond the chest wall and lymph nodes were more likely to live longer than the other patients.

The findings of the Duke study, published in the October Journal of Clinical Oncology, can help physicians select which metastatic breast cancer patients might benefit most from aggressive therapy and suggest restructuring follow-up treatment for patients at high risk for recurrence or new spread of disease, according to the authors.

"Right now high-risk patients are followed with a symptom-based approach--if there's a problem or change in symptoms then tests are done to see why," said lead author Dr. David Rizzieri. "Instead, at-risk patients should be followed very closely, with routinely scheduled physical, radiographic and laboratory tests to catch recurrence early, before symptoms appear. We want to hit the disease early, and hit it hard."

Because of its greater toxicity and a dearth of clinical trials comparing it to standard treatments, high-dose chemotherapy with bone marrow transplant is a controversial treatment for breast cancer patients. Nevertheless, many patients have been demanding the treatment, believing it to be their last hope. At the American Society for Clinical Oncology (ASCO) annual meeting in May, other scientists reported preliminary results of an ongoing randomized clinical trial that demonstrated no survival difference between a high-dose treatment group and a "standard" dose group of metastatic breast cancer patients after an average of 31 months of follow-up.

However, the Duke study has a longer follow-up period and more eligible patients than the study presented at ASCO. In addition, the two studies used different drug combinations for both the initial "induction" chemotherapy treatment and the high-dose chemotherapy regimen. The induction treatment tests the sensitivity of patients' tumors, inducing tumors to begin to die and identifying those for whom high dose chemotherapy is an option.

The purposes of the two studies were also different. The Duke study examined the effect of the timing of high dose chemotherapy. Patients who were in remission after induction treatment were randomized to receive high-dose chemotherapy either immediately or delayed until the disease progressed, while those patients whose disease was slowed or stopped but not eradicated by induction received the aggressive treatment immediately. The clinical trial presented at ASCO compared the effectiveness of high dose therapy with a more standard approach; patients who responded to induction were randomized to receive either conventional or high dose therapy.

"Our current analysis is a baby step forward for the use of aggressive therapy in metastatic breast cancer," said Rizzieri. Because the high doses of anti-cancer drugs are very toxic, a patient's blood cells and immune system must be regenerated afterward by transplanting hematopoetic stem cells--primitive cells capable of making all blood cells. While stem cells can come from a donor other than the patient, all of the patients in the Duke study received stem cells taken from their own bone marrow or peripheral blood.

Rizzieri stressed that even though researchers identified a sub-group of patients most likely to respond well to aggressive therapy, there were patients in all groups who survived disease-free for more than three years. "For example, even though patients with liver metastases did the poorest on average, there are still long-term disease-free survivors in this group using this aggressive approach," he said. No characteristic tied together all long-term survivors, however, indicating that there is still much to be learned, said Rizzieri, who is assistant professor of medical oncology and bone marrow transplantation.

For all 425 patients in the study, regardless of treatment or timing, the new analysis found six factors that contributed to better survival on average. Three were identical to those leading to greater success with aggressive therapy: previous treatment with tamoxifen; no prior chemotherapy; no metastases other than the chest wall and lymph nodes. In addition, having metastatic tumors smaller than two centimeters, estrogen receptors, and more than two years between initial treatment and development of metastatic disease improved the chance for a better outcome for the study population as a whole.

The original Duke clinical trial, which ran from 1987 to 1995, was not specifically designed to identify factors related to better response or survival, but the information was there for the looking, Rizzieri said. Early results of this trial, published in 1996 with an average of 20 months of follow-up, showed that for patients who got immediate high dose therapy, the disease took longer to return or progress, but that delaying aggressive treatment until the first sign of further growth improved overall survival. Long-term results are being analyzed now.

Because of the difference in progression-free versus overall survival, delaying high dose chemotherapy until disease progression makes sense for metastatic breast cancer patients who achieve complete remission after initial induction treatment, said Rizzieri, as long as those patients are monitored closely. New developments might change this, however. Rizzieri added that newer approaches try to minimize disease with high dose therapy, building the foundation for such up-and-coming approaches as gene therapies, vaccines, or inhibitors to blood vessel growth to be used as "mop up" agents after transplant and recovery. The practice of using high dose therapy and transplant early in the course of metastatic disease is therefore an important investigational approach, Rizzieri said.

Co-authors on the study are James Vredenburgh, Gloria Broadwater, Donald Berry, William Petros, Charlotte Gilbert, Mary Affronti, David Coniglio, Gwynn Long and Nelson Chao of Duke. Also Robert Jones and Elizabeth Shpall (cq) of the University of Colorado Medical Center, Maureen Ross of the University of Virginia, Atif Hussein of Columbia Health Care, Aventura, Fla., Peter Rubin of Presbyterian Hospital in Charlotte, N.C., Maha Elkordy of Rex Cancer Center in Raleigh, N.C., and William Peters of the Barbara Ann Karmanos Cancer Institute in Detroit.
-end-


Duke University Medical Center

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.